The risk for urinary tract infections with sodium-glucose cotransporter 2 inhibitors: no longer a cause of concern?
| Title | The risk for urinary tract infections with sodium-glucose cotransporter 2 inhibitors: no longer a cause of concern? |
| Publication Type | Journal Article |
| Year of Publication | 2020 |
| Authors | Sarafidis, P. A., & Ortiz A. |
| Journal | Clin Kidney J |
| Volume | 13 |
| Issue | 1 |
| Pagination | 24-26 |
| Date Published | 2020 Feb |
| ISSN | 2048-8505 |
| Abstract | Sodium-glucose co-transporter-2 (SGLT2) inhibitors improve cardiovascular and renal outcomes in patients with type 2 diabetes, including those with diabetic kidney disease. However, the US Food and Drug Administration and European Medicines Agency warnings about potential adverse effects, such as urosepsis and pyelonephritis, based on post-marketing case reports, may deter physicians from prescribing these drugs. A recent evaluation of two large US-based databases of commercial claims failed to find evidence for an increased risk of urinary tract infection (UTI) or severe UTI in type 2 diabetes patients who were prescribed an SGLT2. |
| DOI | 10.1093/ckj/sfz170 |
| Alternate Journal | Clin Kidney J |
| PubMed ID | 32082549 |
| PubMed Central ID | PMC7025347 |
